### UNITED STATES DISTRICT COURT

#### FOR THE DISTRICT OF DELAWARE

THE JOHNS HOPKINS UNIVERSITY, a
Maryland corporation, BAXTER
HEALTHCARE CORPORATION, a Dolaward

HEALTHCARE CORPORATION, a Delaware:

corporation, and BECTON DICKINSON

AND COMPANY, a New Jersey corporation,:

Plaintiffs,

CELLPRO, INC., a Delaware corporation,

٧.

Defendant.

: Case No. 94-105 RRM

DECLARATION OF DR. GORDON L. PHILLIPS

## DECLARATION OF DR. GORDON L. PHILLIPS

- I, Gordon L. Phillips, M.D., do hereby declare:
- 1. I am the Director of the Blood and Bone Marrow Transplant Program at the Markey Cancer Center and a Professor of Medicine at the University of Kentucky. A copy of my curriculum vitae is attached.
- 2. I am familiar with the CellPro CEPRATE® SC stem cell concentrator, and I have used that device for "purified" autologous stem cell transplantation following high dose chemotherapy treatment for lymphoma and myeloma. (I have also used the CEPRATE® SC device for an allogeneic transplant.) In the future I intend to use the CEPRATE® SC device in other high dose chemotherapy protocols with an emphasis on autologous transplants.
- 3. Compared to conventional protocols, use of the CEPRATE® SC device has the advantages of proven efficacy, reproducibility, and ease of use. The availability of an FDA approved product, such as the CEPRATE® SC device, makes it much easier to get experimental treatment protocols approved, as well as to recruit patients to undergo those treatments.
- 4. There is a compelling public interest in maintaining the availability of the CEPRATE® SC device in view of the emerging consensus that the transplant of inadequately purified stem cell suspensions are a cause of post-transplant failure.

  The CEPRATE® SC device significantly reduces the tumor volume reinfused

into the patient. Moreover, the CEPRATE® SC device is the only readily available product or method for achieving this goal.

I further declare subject to the penalty of perjury that the foregoing is true and correct.

Executed April \_\_\_\_\_\_\_ 1997 at Lexington, Kentucky.

Gordon L. Phillips, M.D.

# Gordon L. Phillips Director, BMT Program University of Kentucky Curriculum Vitae

Office Address:

800 Rose Street

(606) 323-5768

Markey Cancer Center, CC301

Lexington, KY 40536-0093

# I. Biographical Data:

### Home Address:

2112 Island Point Lexington, KY 40502 (606) 268-6002

S.S.N: 447-44-5838
Birth Date: 09-02-44
Marital Status: married

Children: two

### II. Education:

A. Degrees:

1966 BA, University of Oklahoma
1971 MD, University of Oklahoma School of Medicine

B. Special Professional:

1971-1972	Internship, Internal Medicine, University of Uklanoma Medical Center,
	Oklahoma City, Oklahoma
1972-1974	Residency, Internal Medicine, University of North Carolina School of
	Medicine, Chapel Hill, North Carolina
1974	American Board of Internal Medicine
1974-1975	Clinical Fellow, Hematology/Oncology, Washington University School
_	of Medicine, St. Louis, Missouri
1975-1977	Research Fellow, Hematology/Oncology, Washington University
	School of Medicine, St. Louis, Missouri
1979	American Board of Medical Oncology